---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-089425"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2026-08-03T10:43:48+00:00"
generated_at: "2026-08-03T10:45:08.574511+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Supernus to merge with Indivior in all-stock deal; Indivior holders to own 56.5%

## Summary
- Each Supernus share converts to 1.5401 Indivior shares; fixed exchange ratio, no adjustment for market changes.
- Indivior stockholders to own ~56.5% of combined company; Supernus stockholders ~43.5% on fully diluted basis.
- Indivior to pay $1B special dividend to its stockholders pre-closing, funded by $650M Citibank term loan.
- Combined company renamed Supernus, Inc., trades under SUPN; Jack Khattar CEO, Tim Dec CFO; board split 4-4.
- Termination fees: $101M from Supernus, $174M from Indivior under specified circumstances.

## SEC filing metadata
- accession: 0001104659-26-089425
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2026-08-03T10:43:48+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000110465926089425/0001104659-26-089425-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000110465926089425/tm2622009d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-089425
- JSON: https://secwatch.observer/filing/0001104659-26-089425.json
- Plain text: https://secwatch.observer/filing/0001104659-26-089425.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.